Broadly speaking, my research group’s interests are focused on linking behavior to underlying biological substrates. To investigate animal cognition, we use a variety of behavioral tasks that have been shown to rely on particular regions in the brain, or specific pathways in the brain. For example, to support novel therapeutics aimed at treating Alzheimer’s disease we have focused our efforts on tasks known to be dependent on the hippocampus, a region of the brain uniquely susceptible to the pathology of Alzheimer’s disease.   

I joined Biogen in 2008 after six years in the industry with two other companies (Sention; Johnson & Johnson Pharmaceutical Research & Development). I lead a behavioral pharmacology group within the neurodegenerative disease research team, which provides both cognitive assessment of rats and mice to support of our projects in neurodegenerative diseases and assessment of pain in rodents in nerve injury models to investigate neuropathic pain and potential therapies for this pain. I have always found research at Biogen to be highly collaborative, allowing creative and comprehensive approaches to studying disorders of the nervous system.

Education

  • Postdoctoral Fellow, Laboratories of John Bruno and Martin Sarter, The Ohio State University, Columbus, OH, 1997–2001
  • Postdoctoral Fellow, Laboratory of W.G. Hall, Duke University, Durham, NC, 1994–1997
  • Ph.D., Behavioral Neurology, State University of New York, Binghamton, NY, 1994

Selected Publications

See more scientists